Type B dihydrofolate reductase (dfrb) genes were identified following the introduction of trimethoprim in the 1960s. Although they intrinsically confer resistance to trimethoprim (TMP) that is orders of magnitude greater than through other mechanisms, the distribution and prevalence of these short (237 bp) genes is unknown. Indeed, this knowledge has been hampered by systematic biases in search methodologies. Here, we investigate the genomic context of dfrbs to gain information on their current distribution in bacterial genomes. Upon searching publicly available databases, we identified 61 sequences containing dfrbs within an analyzable genomic context. The majority (70%) of those sequences also harbor virulence genes and 97% of the dfrbs are found near a mobile genetic element, representing a potential risk for antibiotic resistance genes. We further identified and confirmed the TMP-resistant phenotype of two new members of the family, dfrb10 and dfrb11. Dfrbs are found both in Betaproteobacteria and Gammaproteobacteria, a majority (59%) being in Pseudomonas aeruginosa. Previously labelled as strictly plasmid-borne, we found 69% of dfrbs in the chromosome of pathogenic bacteria. Our results demonstrate that the intrinsically TMP-resistant dfrbs are a potential emerging threat to public health and justify closer surveillance of these genes.
Trimethoprim
(TMP)
is widely used to treat infections in humans
and in livestock, accelerating the incidence of TMP resistance. The
emergent and largely untracked type II dihydrofolate reductases (DfrBs)
are intrinsically TMP-resistant plasmid-borne Dfrs that are structurally
and evolutionarily unrelated to chromosomal Dfrs. We report kinetic
characterization of the known DfrB family members. Their kinetic constants
are conserved and all are poorly inhibited by TMP, consistent with
TMP resistance. We investigate their inhibition with known and novel
bisubstrate inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase
(HPPK). Importantly, all are inhibited by the HPPK inhibitors, making
these molecules dual-target inhibitors of two folate pathway enzymes
that are strictly microbial.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.